Catalyst Event
Genscript Biotech Corp (1548) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
6/2/2026, 12:00:00 AM
Associate company Legend Biotech announced on June 2, 2026, positive preliminary clinical data for its in vivo CAR-T cell therapy, LB2501, for non-Hodgkin lymphoma, leading to a significant stock price increase.
Korean Translation
2026년 6월 2일, 관계사 레전드 바이오텍이 비호지킨 림프종에 대한 체내 CAR-T 세포 치료제 LB2501의 긍정적인 예비 임상 데이터를 발표하여 주가 급등을 이끎.
Related Recent Events
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM